Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II selpercatinib study in RET fusion-positive advanced non-small cell lung cancer detected by liquid biopsy
jRCT2031210005Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Jan 2021; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210005.